

## PLACEMENT CLEANSING NOTICE

This notice is given by BARD1 Life Sciences Limited (ASX: BD1) (**Company**) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Act**).

The Company announced today a partially underwritten non-renounceable pro rata entitlement offer to shareholders with a registered address in Australia, New Zealand, Switzerland and Hong Kong of 1 fully paid ordinary share in the Company for every 10 fully paid ordinary shares in the Company held on the record date of 5.00pm (AWST) on 21 June 2019, at an issue price of \$0.02 per share, to raise approximately \$2.5 million (before costs).

The Company also announced today the completion of a placement, by which the Company has raised approximately \$5 million (before costs) by the issue of 248,500,000 fully paid ordinary shares (**New Shares**) at an issue price of \$0.02 per New Share.

The Company advises that:

1. the New Shares were issued without disclosure to investors under Part 6D.2 of the Act;
2. this notice is being given under paragraph 5(e) of section 708A of the Act;
3. as at the date of this notice, the Company has complied with:
  - (a) the provisions of Chapter 2M of the Act as they apply to the Company; and
  - (b) section 674 of the Act; and
4. as at the date of this notice, there is no 'excluded information' of the type referred to in sections 708A(7) and 708A(8) of the Act which is required to be disclosed by the Company.

- ENDS -

### FOR MORE INFORMATION PLEASE CONTACT:

**Peter Gunzburg**  
Chairman  
E [peter@bard1.com](mailto:peter@bard1.com)

**Dr Leearne Hinch**  
CEO  
E [leearne@bard1.com](mailto:leearne@bard1.com)  
M +61 400 414 416

### ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian medical technology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1 owns a proprietary tumour marker platform with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes BARD1 autoantibody tests in development for early detection of breast, ovarian and lung cancers. BARD1's vision is to detect cancer early and save lives. For more information on BARD1, see [www.bard1.com](http://www.bard1.com).